OBI-999 is under clinical development by OBI Pharma and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II drugs for Gastric Cancer have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how OBI-999’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OBI-999 overview
OBI-999 is under development for the treatment of solid tumor, breast cancer, pancreatic cancer, gastric cancer, colorectal cancer and esophageal cancer. The therapeutic candidate comprises of Globo H-specific monoclonal antibody conjugated with monomethyl auristatin E (MMAE). It is administered through intravenous route in the form of liquid and is being developed based on thiobridge technology.
It was under development for the treatment of lung cancer and epithelial tumor.
OBI Pharma overview
OBI Pharma is a biopharmaceutical company that develops therapies for the treatment of cancer and infectious diseases. The company’s pipeline products include adagloxad simolenin, an active immunotherapy which is intended for the treatment of metastatic breast cancer and OBI-833, a cancer vaccine for epithelial cancers other than breast and ovarian cancer. It also develops active immunotherapies intended for the treatment of various lung, prostate, pancreatic, stomach and ovarian cancers. The company has collaboration with research institutes including cancer centers to enhance its pipeline products. It operates in the US, Taiwan, Hong Kong, Australia and China. OBI Pharma is headquartered in Taipei City, Taipei, Taiwan.
For a complete picture of OBI-999’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
